(NASDAQ: MRNA) can be described in several ways. A messenger RNA (mRNA) pioneer. A leader in the COVID-19 vaccine market. A cash-rich biotech company. 

One description of Moderna you probably won't hear very often, however, is value stock. After all, shares trade at nearly 66 times the most optimistic earnings estimate for 2023. But is Moderna actually a value stock to buy right now?

There is an argument to be made that Moderna is a value stock. It just requires looking into the future a bit.

Continue reading

Source Fool.com